Search Results - igg4

2 Results Sort By:
IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
Abstract: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics